Osypka AG

Osypka AG specializes in the TME Temporary Myocardial Electrode, a device used for temporary cardiac monitoring and stimulation during surgical interventions. This product is tailored for short-term clinical needs where precise heart function assessment or stimulation is required.

Osypka AG is based in the United States, which means its devices are subject to FDA regulations. The TME Temporary Myocardial Electrode is classified as a Class II device, indicating it poses moderate risk and requires compliance with specific FDA requirements, including the 510(k) clearance pathway for market authorization.

Osypka AG’s TME Temporary Myocardial Electrode is listed under the FDA’s 510(k) pathway, meaning it has undergone the required pre-market notification process to demonstrate substantial equivalence to a legally marketed predicate device. This classification ensures its compliance with U.S. regulatory standards.

The TME Temporary Myocardial Electrode is classified as a Class II medical device by the FDA. This classification is based on its intended use—temporary cardiac monitoring and stimulation—which carries moderate risk. Class II devices require special controls beyond general controls to ensure safety and effectiveness, including performance standards and post-market surveillance.